Compare Alcon AG (ALC) vs Allegion PLC (ALLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Allegion PLC — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Allegion PLC trades at $135.08 (market cap $11.97B). The key difference: Alcon AG is far larger — about 2.7× Allegion PLC's market cap, and Allegion PLC pays the higher dividend (1.52%). Which is the better fit depends on your goals.
| ALC | ALLE | |
|---|---|---|
Market Cap | $32.69B | $11.97B |
Sector | Health | Industrials |
52-Week High | $92.22 | $179.77 |
52-Week Low | $62.02 | $125.65 |
Enterprise Value | $36.28B | $13.69B |
Dividend Yield | 0.54% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ALLE trades at $139.32, down 0.9% on the day, with a bullish technical signal and strong fundamentals including a 15.24% net margin and 34.18% ROE. Recent earnings show mixed results with a Q3 2025 beat but Q4 2025 and Q1 2026 misses. The company maintains robust cash flow from operations and has announced a $0.55 dividend for June 2026. News highlights product innovations like the Schlage Sense Pro smart deadbolt and participation in industry conferences.
Outlook is supported by analyst consensus with a $152.50 price target and no sell ratings, though risks include rising costs and international market weakness. The stock offers growth potential from Americas strength and acquisitions, but investors should monitor margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
